<DOC>
	<DOCNO>NCT02731742</DOCNO>
	<brief_summary>This non-randomized , open-label study MK-1966 use combination SD-101 treatment advance malignancy . The study include initial Dose Evaluation phase determine maximum tolerate dose ( MTD ) /maximum administer dose ( MAD ) evaluate Dose Limiting Toxicities ( DLTs ) four dose combination MK-1966 SD-101 . Following determination MTD/MAD , approximately 20 participant enrol two expansion cohort confirm/refine MTD/MAD .</brief_summary>
	<brief_title>Dose Evaluation MK-1966 Combination With SD-101 Participants With Advanced Malignancies ( MK-1966-001 )</brief_title>
	<detailed_description />
	<criteria>Has histologically cytologicallyconfirmed advanced malignancy progress standardofcare therapy/treatments available therapy likely convey clinical benefit Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Has life expectancy â‰¥ 6 month Female participant must pregnant ( negative urine serum human chorionic gonadotropin test screening within 72 hour prior receive first dose study therapy ) Female male participant reproductive potential must agree use adequate contraception course study 120 day study last dose study therapy Has ability submit archive fresh tumor sample screen period Has chemotherapy , radiation , biological cancer therapy within 4 week prior first dose study therapy , recover Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 good adverse event due cancer therapeutic administer 4 week earlier Has participate study investigational agent receive study therapy use investigational device within 28 day study start Is expect require form antineoplastic therapy study Is chronic systemic steroid therapy excess replacement dos , form immunosuppressive medication Has history malignancy , unless potentially curative treatment complete , evidence malignancy 5 year Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has severe hypersensitivity reaction treatment another monoclonal antibody Has active autoimmune disease require systemic treatment past 2 year Has active infection require therapy Has active , current pneumonitis , history ( noninfectious ) pneumonitis require steroid Has prior stem cell bone marrow transplant Is positive Human Immunodeficiency Virus ( HIV ) and/or Hepatitis B C Has know psychiatric disorder would interfere fulfil requirement study Is regular user illicit drug recent history substance abuse Has symptomatic ascites pleural effusion Is pregnant breastfeed expect conceive father child within project duration study Has clinically significant heart disease affect normal activity Has major surgery ( require least 3 day hospital stay ) past 28 day Has receive live vaccine within 30 day prior first dose study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>